期刊
DIABETES TECHNOLOGY & THERAPEUTICS
卷 23, 期 9, 页码 652-660出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2021.0107
关键词
Continuous glucose monitoring; Centers for Medicare & Medicaid Services; Insurance coverage; Type 1 diabetes; Type 2 diabetes
资金
- Dexcom, Inc.
The article discusses the limitations and inconsistencies of CMS eligibility criteria for CGM in relation to current scientific evidence, and proposes workable solutions to improve the safety and care of all individuals with diabetes.
Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for CGM coverage required by the Centers for Medicare & Medicaid Services (CMS) ignore conclusive evidence that supports CGM use in various diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the CMS eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据